Phase I/II, open-label, Multi-center, Two part dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy study of AZD4877 in patients with acute myelogenous leukemia (AML)

Study identifier:D2782C00007

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I/II, Open-Label, Multi-Center, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of AZD4877 Administered on Days 1, 2 and 3 in Adult Patients with Recurrent or Refractory Acute Myelogenous Leukemia (AML) Excluding Promyelocytic Leukemia

Medical condition

acute myelogenous leukemia

Phase

Phase 1

Healthy volunteers

Study drug

AZD4877

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jul 2007

Primary Completion Date: -

Study Completion Date: 01 Jul 2009

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Houston, TX, United States

Location

Research Site

San Antonio, TX, United States

Location

Research Site

Chicago, IL, United States

Location

Research Site

Toronto, ON, Canada

Arms	Assigned Interventions

"There is no result for the study"

Documents available

US and Canada only
Download
https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1301&filename=CSR-D2782C00007.pdf
Download
CSR-D2782C00007.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Cancer Study Locator Service

1-877-400-4656

astrazeneca@emergingmed.com

Contact Backup

AstraZeneca Information, Outside US

1-800-236-9933

Investigators

Principal Investigator

Gregory A Curt

AstraZeneca

Phase I/II, open-label, Multi-center, Two part dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy study of AZD4877 in patients with acute myelogenous leukemia (AML)

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Research Site

Research Site

Research Site

Research Site

Documents available

US and Canada only

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1301&filename=CSR-D2782C00007.pdf

CSR-D2782C00007.pdf

Trial Results Summaries

Contacts

Contact

Contact Backup

Investigators

Principal Investigator